Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Shaji Kumar, Wilson I. Gonsalves et al.|American Journal of Hematology|2023Cited by 56
Risk factors for severe infection and mortality In patients with <scp>COVID</scp>‐19 in patients with multiple myeloma and <scp>AL</scp> amyloidosisMatthew Ho, Shaji Kumar, Saurabh Zanwar et al.|American Journal of Hematology|2022Cited by 23
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Shaji Kumar, Matthew Ho et al.|Leukemia|2021Cited by 20
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Shaji Kumar, Saurabh Zanwar et al.|Blood Cancer Journal|2021Cited by 18
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Shaji Kumar, Saurabh Zanwar et al.|Blood|2022Cited by 8